[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ganglioneuroma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ganglioneuroma":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100239986","project-every-child-for-younger-patients-with-cancer-100239986",false,"NCT02402244","Project: Every Child for Younger Patients With Cancer","The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study","Inclusion Criteria:\n\n* Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem\n* Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority\n* Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:\n\n  * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one \"1\" (borderline), two \"2\" (carcinoma in situ) or three \"3\" (malignant)\n  * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant\n  * All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant\n  * The following other benign\u002Fborderline conditions:\n\n    * Mesoblastic nephroma\n    * Teratomas (mature and immature types)\n    * Myeloproliferative diseases including transient myeloproliferative disease\n    * Langerhans cell histiocytosis\n    * Lymphoproliferative diseases\n    * Desmoid tumors\n    * Gonadal stromal cell tumors\n    * Neuroendocrine tumors including pheochromocytoma\n    * Melanocytic tumors, except clearly benign nevi\n    * Ganglioneuromas\n* Subjects must be =\\\u003C 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \\[NCTN\\]) therapeutic study, for which there is a higher upper age limit\n* All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission\n\n  * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1","ALL","25 Years",{"count":19,"type":20},75000,"ESTIMATED","OBSERVATIONAL","This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Adrenal Gland Pheochromocytoma","Carcinoma In Situ","Central Nervous System Neoplasm","Childhood Immature Teratoma","Childhood Kidney Neoplasm","Childhood Langerhans Cell Histiocytosis","Childhood Mature Teratoma","Congenital Mesoblastic Nephroma","Desmoid Fibromatosis","Ganglioneuroma","Lymphoproliferative Disorder","Malignant Neoplasm","Malignant Solid Neoplasm","Melanocytic Neoplasm","Myeloproliferative Neoplasm","Neoplasm of Uncertain Malignant Potential","Neuroendocrine Neoplasm","Stromal Neoplasm","RECRUITING","2026-05-01",{"date":45,"type":46},"2026-05-05","ACTUAL",{"date":48,"type":46},"2015-11-03",{"date":50,"type":20},"2030-12-31",{"name":52,"class":53},"Children's Oncology Group","NETWORK",278,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100454087","siopen-bioportal-an-international-registry-linked-to-a-virtual-biobank-for-patients-with-peripheral-neuroblastic-tumours-100454087","NCT05192980","SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours","BIOPORTAL","Inclusion Criteria:\n\nI-1. Patients with PNT: ganglioneuroma or ganglioneuroblastoma or neuroblastoma, I-2. At the time of initial diagnosis of neuroblastic tumour, or at relapse\u002Fprogression if not yet registered I-3. Written patient informed consent, or parents or legal representative written informed consent and assent of the child, adolescent or young adult\n\nNon-Inclusion Criteria:\n\nR-1. (Adult) Patients with olfactory neuroblastoma R-2. Central nervous system (CNS) neuroblastoma (as per the WHO classification)",{"count":63,"type":20},600,"INTERVENTIONAL",[66],"NA","The SIOPEN BIOPORTAL is a prospective non-therapeutic multi-centre international study aimed at developing an international Registry linked to a Virtual Biobank for all the patients with peripheral neuroblastic tumor within countries of the SIOPEN network. The overall aim of this study is to provide a GDPR-compliant framework to collect basic clinical annotations, biological and genetic features and information about the location on biospecimens for all the patients with a peripheral neuroblastic tumor including neuroblastoma, ganglioneuroblastoma and ganglioneuroma in the SIOPEN network.\n\nThis study will support data and sample management and intensify cross-borders data and sample sharing fostering translational and clinical research. The post-hoc hypothesis formulated based on the data generated in this study will be used as statistical basis for future precision medicine programs based on improved biological characterization, patient stratification and therapeutic management.",[69,70,33],"Neuroblastoma","Ganglioneuroblastoma","2025-07-17",{"date":73,"type":46},"2025-07-22",{"date":75,"type":46},"2023-11-02",{"date":77,"type":20},"2038-11-02",{"name":79,"class":80},"Institut Curie","OTHER",38,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":93,"studyType":21,"phases":4,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100538891","abdominal-neuroblastoma-laparoscopic-surgery-risk-factors-stratification-100538891","NCT06296732","Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification","ANLAP-R","Inclusion Criteria:\n\n1. Patients with neurogenic tumors meeting the criteria of groups I-III:\n\n   Group I\n   * low or moderate risk group according to pilot difficulty scoring system (less than 5 points, see supplementary material);\n   * no IDRF;\n\n   Group II:\n   * low or moderate risk group according to pilot difficulty scoring system (less than 5 points);\n   * patients with any number of IDRFs and without central tumor location and\u002For tumor extension across the midline and\u002For tumor volume (cm3)\u002Fpatient height (m) ratio = 28 or more.\n\n   Group III:\n   * 2 and more IDRF + central tumor location and\u002For tumor extension across the midline;\n   * 2 and more IDRF + tumor volume (cm3)\u002Fpatient height (m) ratio = 28 or more;\n   * 2 and more IDRF + 2 and more other risk factors according to pilot difficulty scoring system;\n   * 1 IDRF + tumor extension across the midline + tumor volume (cm3)\u002Fpatient height (m) ratio = 28 or more.\n2. Age from 0 to 18 years.\n3. Preoperative imaging (abdominal contrast-enhanced computed tomography (CT), performed no later than 14 days before the planned surgery).\n4. Indications for surgery based on the decision of multidisciplinary experts board in centers- participants.\n5. Written voluntary informed consent of the patient and \u002F or his legal representative.\n\nExclusion Criteria:\n\n1. 3 and more IDRF + central tumor location and\u002For tumor extension across the midline and\u002For tumor volume (cm3)\u002Fpatient height (m) ratio = 28 or more.\n2. Severe concomitant pathology, increasing anesthesiologic and surgical risks, via the desicion of the research physician or conclusion by multidisciplinary team in centers- participants.\n3. Tumor volume does not technically allow to provide minimally-invasive surgery, based on the conclusion of multidisciplinary experts board team in centers- participants.\n4. Therapy strategy: observation\n\n   \\-","1 Day","18 Years",{"count":92,"type":20},200,"5 Years","Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (\\>4-7 cm) are considered as common contraindications for minimally invasive surgery in neuroblastoma. However, the recent studies have shown that presence of IDRF is not an absolute contraindication for laparoscopic surgery. This open-label, nonrandomized, observational, phase III evaluates role and weight of different surgical risk factors (including IDRF, tumor size, tumor localization, tumor volume\u002Fpatient height ratio, previous open surgical procedures, previous chemotherapy etc.) in the laparoscopic neuroblastoma resections. The aim of this study is to create novel risk factors scoring system for laparoscopic surgery in abdominal neuroblastoma.",[69,33,70],[69,33,70,97,98,99,100,101,102],"Laparoscopic surgery","Minimally-Invasive surgery","IDRF - image-defined risk factors","Risk factors","Difficulty scoring system","Complete resection","2024-05-17",{"date":105,"type":46},"2024-05-20",{"date":107,"type":46},"2023-10-19",{"date":109,"type":20},"2031-11-01",{"name":111,"class":80},"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",1]